Hello, everyone, and welcome to Grifols' Full Year 2022 Conference Call. Thank you very much for taking the time to join us today. This is Nuria Pascual speaking, Investor Relations and Sustainability Officer. And I'm joined by Thomas Glanzmann, our Executive Chairman; Victor Grifols Deu and Raimon Grifols, our Co-CEOs and Alfredo Arroyo, CFO of Grifols. We anticipate that this call will last for about 60 minutes. There will be a presentation of approximately 35 minutes followed by a Q&A session. As a reminder, this call is being recorded. And the materials for the call are on the Investor Relations section of grifols.com. Before we start, I draw your attention to the forward-looking statement disclaimer on Slide 2 in the slide deck of our release. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of these statements. With that, I would like to turn the call over to Thomas.

Thank you, Nuria, and thank you, everyone for joining the call today. By now, you are all aware that we have had a change of the guard in the position of Executive Chairman. The Board has greatly respected the resignation of Steve Mayer, who made the decision to step down for health and personal reasons. Effective February 22, I stepped into the role and I would at this point like to thank Steve for the valuable work and contribution he made over the past month and 12 years as a Grifols Board member. Needless to say, I and the Board wish him all the best as he moves on to another chapter in his life. For those who do not know me or I have not had an opportunity to meet at one of our investor meetings, let me briefly introduce myself. I've been on the Grifols Board for almost 17 years and in recent years was the company's Vice Chairman. I have been associated with the plasma and diagnostics industries since the late 1980s, and I have been a CEO of plasma, biologics, renal, and diagnostics companies during my career. In the past years, my focus has been on investing in startup companies with innovative new medtech technologies and serving on a number of boards, including Alcon, Inc., which I know some of you also know. Throughout my career, my priority has always been to build and grow companies sustainably and profitably, which I also intend to do in partnership and close cooperation with the CEOs, the Grifols leadership team, and the Board. Grifols is on the rebound. After some tough years, we are now setting up once again for a sustainable and financially sound growth-oriented future with our operational performance plan and the recently announced restructuring. I want to recognize and thank Steve, the CEOs, and Alfredo for making the plans and addressing our challenges head-on with tough but needed measures and clear priorities to ensure that we again find ourselves on a winning path. In our presentation, we will update you on the progress and outlook, which I personally think is very encouraging. Although we, as a leadership team, recognize that we clearly still have work to do and be assured it will happen and it will get done. I am committed, with the CEOs and Alfredo, to stay the course on all the plans, priorities, and measures that we have announced and that currently are being implemented. There is no way back. And as you will see in our presentation, we are visibly committing to targets and numbers associated with the announced measures. I would also like to spell it out once again, and this is very important, that we are laser-focused on deleveraging the company with both improved operating measures and evaluating broader corporate initiatives, which we expect to complete in 2023. Together with the CEOs and Alfredo, we will be monitoring our progress on a weekly basis. If necessary, we will undertake immediate course corrections to ensure we deliver on our objectives. I am also committed to keeping open communication with you, and we as a team will, as promised, be updating you regularly on our announced quarterly calls of the business and financial status and its progress. Finally, I want to reiterate, and again this is very important, that the Board, which initiated and has guided the creation of the operational improvement plan, continues to be in full support of executing the plans and measures that we have announced recently. I know that Alfredo, Nuria, Danny, and the investor team will continue to address questions you have in between our calls and I will personally meet a number of you, as I will occasionally travel with our investor team. As you can hear, we are committed to a seamless transition and optimistic about the future. I am excited to work with Victor, Raimon, Alfredo, and the entire Grifols team to make sure that we deliver on our commitments to all our constituents. Let us now turn to our presentation that I will share with Victor and Alfredo, and then we will be happy to take your questions. So let me start with an overview of our focus areas and Grifols' full year 2022 annual results, which we show you on Slide 4. 2022 was a pivotal year for Grifols, and I want to give a lot of credit to the entire Grifols team. We set clear action priorities and took important steps to improve the company's performance.

Thank you, Thomas. Good morning or good afternoon to everyone and thank you for joining us today. Now we will turn to Slide number 8 to talk about the performance at a high level of Grifols. I am very proud to say that Grifols performed strongly in 2022 while operating in a challenging macroeconomic environment. Grifols’ total revenues grew by 12.4% at constant currency, and 23% on a reported basis, reaching record levels of sales of EUR6.1 billion and EUR5.7 billion, if excluding Biotest, driven by Biopharma’s performance, robust underlying demand, favorable pricing, product mix, and a notable Biotest contribution, plus an FX tailwind. Now turning to Slide number 9 to make a deep dive on Biopharma. Biopharma stood out with full year robust operational growth of 10%, 22% on a reported basis, driven by a strong fourth quarter. In Q4, it delivered a 14% increase in revenues, which was close to 30% on a reported basis. Please note that all those numbers on the slide exclude Biotest. We remain positive as we see this momentum reinforced, evident by a strong fourth quarter across all key proteins, especially IG, our flagship which grew by 18% in the fourth quarter and by 13% in the full year. This was driven by a significant increase in plasma supply with strong growth recorded in our leading IgG brands. Demand has been robust and this is expected to continue, backed by the fact that many patients remain undiagnosed while demand for treatment for primary immunodeficiency and secondary immunodeficiency continue to grow. Also noteworthy is how new products continue to increase their contribution, driven by our plan to grow our subcutaneous immunoglobulin, Xembify, market share and revenues. This product in particular offers an improved patient experience for those wanting the convenience of home-based treatments. The increase in plasma supply also contributed to our albumin portfolio growing by 5% with higher demand in the Asia Pacific area driven by China and improved product needs supported by the launch of albumin in plastic container. Alpha-1 and specialty proteins delivered mid to high-single digit growth due to favorable customer mix, higher demand, and price increases. Supplement to the main franchise growth, I would also like to highlight the increasing contribution to the business, unit growth of the recent new launches like fibrin sealant and thrombin in the surgery and bleeding control market, TAVLESSE, and the hyperimmune portfolio. Now moving to Slide 10, continuing in Biopharma, but deep diving into plasma specifically. As mentioned, plasma collections positive evolution continues, increasing by 25% in 2022. This upbeat trend was driven by greater plasma volumes from existing centers complemented by new and recently acquired plasma centers. The lifting of the U.S. border restrictions in mid-September delivered an increase in volumes of plus 23% in that area compared to 2021. As plasma collection volumes are meaningfully increasing, we are now focused on cost per liter reduction, tackling donor compensation and optimization of labor as well as fixed costs. Since its peak in July this year, donor commitment compensation declined by 20% driving total cost per liter down by 10%. Managing other plasma operations cost is also key as this represents close to 65% of the plasma costs. This also contributed, to a lesser extent, to this cost per liter reduction. We firmly believe that this is a positive sign for ourselves, especially in this challenging macroeconomic context, including an annual inflation impact of around 8% to 10%. Looking forward, we're confident on a further cost per liter reduction with the aim to revise it, amplified by our ambitious operational improvement plan in the plasma area, focused on driving higher efficiencies in our donor centers and creating a leaner and more efficient plasma organization. In summary, we have moved away from the plasma security of supply mindset we had to adopt during the pandemic to provide life-saving medicines to our patients. We now have evolved into a sustainable plasma collection operation, focused on donor center productivity, carefully tailoring volumes to meet sales growth and to drive margin expansion. Now turning to Slide 11 to cover innovation for Biopharma. We continue to advance on our innovation pipeline. Personally, I believe the Grifols R&D pipeline has never been in such a strong position for all clinical trial phases, representing a key lever for sustainable and profitable growth in the short, medium, and long term. There are several expected milestones marked in capital letters in our 2023 agendas. We expect final results from Xembify bi-weekly dosing study. The first patient enrolled and treated in the Xembify secondary immunodeficiency CLL study as well as the final results of our IVIG-PEG study. We also expect to finalize enrollment of the PRECIOSA trial in the first half of 2023, while the SPARTA trial for alpha-1 in the second half of 2023. For the Biotest Trimodulin ESsCAPE Phase III trial, we expect study initiation during half 1 of 2023 while we expect to submit the FDA BLA application for Yimmugo. For the Biotest Fibrinogen trial, we expect complete top-line data in the second half of 2023. And also, I would like to mention the milestone for the two GigaGen projects, the 564 and the 2339, as we expect to IND submission and pre-IND submissions, respectively, during the second half of this year 2023. The financial reading from all those developments achieved in innovation in 2022, plus the ones expected for the year 2023 is a very solid combination of life cycle management strategy to reinforce leadership in our most cell proteins in terms of plasma liters equivalent, together with a robust and diversified pathway to bring new proteins such as Trimodulin, Fibrinogen, or ATIII in Sepsis that we expect to have a significant contribution in the midterm to the company's plasma economics and hence, to its gross margin improvement. Now turning to Slide 12 for diagnostics. Diagnostic performance has been impacted due to non-recurring sales of the NAT technology to detect COVID-19 and the termination of mandatory Zika virus testing, which was partially offset by a year from blood typing solutions, which delivered a strong revenue. Excluding these two items, the business unit declined by 4.6% at constant currency in 2022, impacted by pricing in exchange for extending a large contract with a key NAT donor screening customer for 15 years, coupled with weak performance of recombinant proteins resulting from the joint business collaboration on a new R&D project. Blood typing solution was the main driver of the business unit, recording robust double-digit growth across most geographies. Of note, the U.S. and Mexico with everything gaining market share globally for that division. As I mentioned in the third quarter business update, I would like to emphasize the importance of launching AlphaID At Home, an OTC free service to assess genetic risk of developing alpha-1 deficiency in the U.S. as well as the new DG Gel 8 card in the U.S. market. Now turning to Slide 13 to comment on Bio Supplies. Bio Supplies increased by 13% at constant currency and by 26% on a reported basis, following the acquisition of the remaining 51% capital of Access Biologicals, which positively impacted performance of Bio Supplies, cell culture media, and plasma for diagnostics. The rationale of the acquisition of Access Biologicals was to achieve higher margins through vertical integration to gain commercial knowledge, to grow in the cell culture market in-vitro diagnostics and diagnostic R&D solutions, and to enhance and reinforce the Bio Supplies portfolio with a more robust offering of biological products, while boosting Grifols' standing as a reportable supplier of biological products. We are firmly convinced of Bio Supplies potential, and it will be a high future growth engine for the company.

Thanks, Victor. Hello to everyone. We're on Slide 15. In Q3 earnings call, we provided guidance on revenues, EBITDA, and leverage for the year 2022. Now we can confirm that we met and even exceeded the targets, EUR6.1 billion revenues, 20.6% margin and 7 times leverage. Slide 16 shows the 2022 P&L with accelerated growth and improved profitability. Revenues on Q4 revenues were up by 20.9% at constant currency versus prior year, reaching EUR1.7 billion. On a reported basis, this growth represented a 34.7% increase. Top line for the full year increased by EUR1 billion, reaching EUR6 billion, representing close to 23% increase versus prior year, with 12.4% growth at constant currency on the back of strong organic growth from Biopharma, positive Biotest contribution, and a positive FX. On gross margin, this gross margin was impacted by high plasma costs collected in 2021 and the first half of 2022 due to the 10-month lag inventory accounting, higher plasma costs mainly coming from higher donor fees and labor cost inflation. Also, the termination of COVID-19 and Zika testing business impacted total gross margin by 200 basis points in 2022 versus prior year. Reported EBITDA grew up to EUR1.2 billion, with 16.5% growth at constant currency and a 20.6% adjusted margin, improvement based on operational leverage, including SG&A cost savings and R&D prioritization that partially offset higher plasma costs and lower diagnostic margins. Net profit increased by 10.4%, up to EUR208 million, hit by higher financial expenses linked with Biotest acquisition. Now moving to Slide 17. The 2022 EBITDA reported increased by EUR237 million to EUR1.2 billion with a 21% margin. Positive contribution to EBITDA from all business units except diagnostics, coupled with OpEx savings. Slide 18, deleveraging remains a top priority with a 4 times target by the end of 2024. Reported leverage declined to 7 times at the year-end. Leverage will further decline in 2023 on the back of higher EBITDA and deleveraging transactions. A strong liquidity position amounting to EUR1.6 billion at year-end with no significant debt maturities until 2025. Moving to Slides 19 and 20. In the next couple of slides, I'm going to provide you with some technical difficulty a few days ago that will bring more than EUR400 million of annualized cash savings. This plan is already in deployment and expected to be completed throughout 2023. Out of the EUR400 million, about EUR100 million of this saving will be recognized in 2023 P&L. The reasons why only EUR100 million will be in DGS P&L is due to the timing of the initiatives implementation and the 10-month accounting lag of our inventories related to plasma. Many of you may wonder why plasma cost savings take 10 months to flow through the P&L. This transition is as follows: out of 10 months, three months for plasma raw related to collections, testing, quarantine time, and inventory on hold. And seven months for the fractionation, purification, filling, packaging, and pro-release. This 10-month inventory accounting treatment is in line with the industry accounting standards. Cash savings of EUR250 million will be captured in 2023. 75% will come from lower plasma costs that will impact our inventory, meaning that our inventory will be lower, thanks to these lower plasma costs. The majority of the annualized cost savings, EUR300 million will be recognized in 2024. So out of the EUR400 million again, EUR100 million will be booked in 2023 and EUR300 million will be booked in 2024. This plan will deliver a more efficient, effective, and competitive organization to support Grifols long-term strategy. The plan focuses on three major projects: optimizing plasma costs and operations, streamlining corporate functions, and capturing operational efficiencies across the organization. For the first project, our goal is to create the most efficient technological advance, donor-friendly, highest quality world-class plasma procurement operations. To this end, some of the key initiatives currently being deployed and in deployment are driving efficiencies in our plasma centers by creating more digitalized and efficient processes to reduce down time, increasing throughput, decreasing staffing costs, and opening hours while enhancing the donor experience. Another one would be donor compensation optimization. Another initiative will be closing and consolidating underperforming donor centers, with 18 centers already closed in the fourth quarter of 2022 and several additional centers scheduled to be closed or consolidated in the first half of 2023. These initiatives together with others will increase the productivity by center, the connections by center, and create a leaner, more accountable, and more effective plasma organization. Total annualized savings in plasma will amount to EUR300 million. The second project of this plan that amounts to EUR60 million annualized cost savings is focused on streamlining corporate functions, reduce indirect spend and headcount, and covering other cost savings initiatives, including centralizing, automating functions, enhancing services across functions and business units, consolidating vendors, streamlining reporting structure, delayed reorganization, and eliminating redundant activities. The third project of the plan that amounts to EUR40 million annualized savings, targets direct and indirect procurement on strategic sourcing, also targeting logistics, capturing cost improvements through flexible supply chains by new routes and rationalizing the real estate footprint. A one-time charge of approximately EUR140 million will be required to deliver these cost savings initiatives. This charge will be booked in Q1 2023. Moving into Slide 21, 2023 percent guidance. We're confident in this guidance, strong sales growth, and further margin expansion where most of these improvements will come in the second half of the year due to the phasing of the initiatives' implementation and loan inventory accounting cycle as already explained. We expect a total revenue growth of 8% to 10% at constant currency and 10% to 12% for Biopharma. The main drivers for this will be plasma supply, strong underlying demand, pricing, and product mix. In the first half of 2023, we expect EBITDA standalone margin around 20%, still impacted by high plasma costs from 2022 considering the inventory accounting of these 10 months. However, this will be followed by significant margin expansion in the second half of the year when we expect an EBITDA margin of 23% to 25%. The main reason for this improvement is the meaningful plasma cost decline that already started in Q4 2022, plus the continued reduction in 2023 accelerated by the execution of the operational improvement plan. As I already mentioned, we expect to recognize EUR100 million in cost savings in the P&L of 2023, mostly in the second half. All in all, we expect the full year 2023 adjusted EBITDA margin in the range of 21% to 23%, reaching EUR1.4 billion. Considering the EUR400 million annualized cash cost savings, we estimate that the EBITDA will boost up to EUR1.7 billion with a margin of 27% to 28%. With this, I hand over to Thomas for the closing remarks.

Thank you, Alfredo. In closing, I want to first thank our entire Grifols team for making it all happen. Without everyone's efforts, focus, and dedication, we would not be able to make the progress we're able to report today. We are delivering a step change in performance. As we enter 2023, we are very well positioned and confident that we will keep building on this positive momentum. Looking at 2023, we believe the company has a solid foundation to build Grifols' future with an organization that is more accountable, efficient, agile, and effective. I want to make it clear that both Grifols' long-term strategy and the measures in place have not changed at all and we are executing our plans and commitments with the full support and at the direction of the board. Our focus for 2023 is also crystal clear. We will execute on our operational plan and deliver the EUR400 million in cash and cost savings. We will deliver on our guidance, and you should see a significant margin improvement in the second half of 2023. Finally, 2023 is the year where we will deleverage the company. You should know that there is no turning back for us; as they say, the train has left the station and is accelerating. Management and the Board are fully invested and laser-focused on creating value and making our commitments a reality. In closing, Grifols is on the rebound, and we are excited about taking the company forward and writing another successful chapter in the company's long growth history. With that also goes our commitment to keep you informed of our progress with these calls, which I hope you find valuable. So finally, let me thank you for your attention. I will now turn it back to Nuria, who will open it up for questions.

Thank you, Thomas, and thank you all for your time. Let's just start the Q&A session.

Thank you. Can you hear me? Thanks. Thanks for doing the call. Much needed. Just on the midterm targets, historically, they've been for EBITDA margins exceeding 30%. So, Thomas and team, if you execute to your plan, when do you see this target being reached at the earliest? Is it something that is 25 and beyond or could it come sooner? And then, Thomas, your last line about looking at accelerating deleverage. I know there's been discussions around a Juul share structure collapse or possibly even divestitures in diagnostics. I think they've been put off the table at least near term. But given your comments about the train leaving the building and really being committed to accelerating deleverage, could either of these options still be undertaken in 2023? Thank you.

Peter, if you don't mind, I will take your first question regarding the midterm guidance. As I said, the EUR1.7 billion, which will account for the annualized EUR400 million, translates to 27% to 28%. If we think about operational improvement in 2024, we can get to 28% to 29%. To come back to the 30%, this will come from 2025 onwards, while at the same time, we will launch the two new products from Biotest.

Peter, thank you for the question on the deleveraging. Let me just say, first of all, all options are on the table, and we are looking at them as we go forward here. The collapse of the shares is also something that we committed to and will do. But the trading value has got to be right, and it has to be valuable for all shareholders involved in such a transaction. But we are very much looking at everything at the moment working very hard to make it happen here, and we will make it happen in 2023.

Hi. Thank you very much for taking questions. Maybe we could go back to the leverage target. I think you said there turn 4 times, by the end of 2024. What does that mean in terms of the past this year? And I suppose that 4 times does that rely on a transaction coming through? And then just to clarify your comments to heat. So does that mean you said that there will be a collapse to share costs? So can I just confirm is that this year or that's just at some point in the future? Thank you.

So Rosie, thank you for the question. I will just address the piece on the collapse and then, I'll pass it on to Alfredo just to pick up your other point. So on the collapse, it all depends on the trading value of the shares. Right now, where we are, that is obviously not of interest. So we are continuing to monitor how the shares progress, and we will then make the decision at the right time when it makes sense for everybody.

Regarding the deleverage target for 2024, the 4 times remains intact. This will be achieved as it will be the combination of both the EBITDA increase plus deleverage transactions.

Hi. Thank you so much for taking my questions. Just one clarification on the transaction this year. Can I check if you are also considering a straight equity raise? I know that's been also discussed by many investors. You talked about the dual share collapse and potential divestments of business units that you have, but can we just triple check on a straight equity raise? And then maybe you can help us understand a little bit more as to what's driving that EUR250 million of cash savings you're expecting this year. We see your peers reporting weak cash flow as they're rebuilding inventory. Perhaps you can remind us where you are in terms of the level of inventory that you hold and if you expect to return to pre-COVID levels? Thank you.

Elizabeth, thank you. I will just address briefly the first part of your question and then pass it on to Alfredo. As I said before, everything is on the table, and it all depends on the value that we can create and what makes the most sense for the company.

Regarding the cash savings this year, the EUR250 million around 80% will come from plasma cost reduction that, as I said, that it takes time to go through P&L. However, we take it as a lower inventory upfront in 2023. The rest, up to EUR250 million, will come from the G&A savings and other savings across the board. I already mentioned so that accounts for EUR250 million. Regarding your inventory, yes, as you saw in our cash flow in 2022, we built up a significant inventory just to recover the levels of pre-COVID times. So for the 2023 cash flow year, the inventory growth will be very limited because we're already in line with the inventory that we need to commit to our sales, okay? So that's on the inventory side. We'll see, I would say, a positive trend versus the previous year.

Hello. Thank you for taking my questions. I had two. Firstly, I was just wondering if you come back to one aspect of the guidance for 2023. You talked about 10% to 12% constant currency growth in your plasma business. But I wonder how you reconcile that with the growth in collections that you've said you've been running at probably 20%, 25% up on collections. Yet you're only pointing to 10% to 12% growth on the plasma revenue side, given the pricing environment and demand environment, that seems fairly conservative given the amount of plasma you've got. So I was just wondering if you could sort of reconcile those two figures for me. And then the second question, maybe one for Alfredo. I guess it pertains to the leverage, but I was just wondering if you could clarify exactly how you calculate the EBITDA number that you've used to calculate your year-end leverage ratio. I think it caught us by surprise and probably caught you by surprise, given you were guiding to 7.9 times mid-year and you came in at 7.1 times. So the debt hasn't changed much, but obviously, something has gone on with EBITDA. So if you could just clarify exactly how you calculate the EBITDA that you use in your leverage ratio, that would be helpful for us all, I think.

Thank you, Tom. This is Victor. I will be answering your first question about linking the 25% volume growth in plasma for 2022 compared to the 10% to 12% sales growth in biopharma for 2023. The 25% volume growth that we have seen and realized during 2022 basically, as Alfredo was saying in the previous question, has been devoted to rebuilding our inventories that were affected very significantly by the pandemic. So basically, this is going to capitalize the inventory buildup. So part of that 20% growth is related to that. And then as I have said, some centers are going to be consolidated. Therefore, we don't need that much amount of plasma for 2023 to meet our sales. So there is really, we are now tackling sales really directed to the volume needed.

Hi, Tom. Good to talk to you again. Regarding the leverage calculation, the 7.1 times for the year-end 2022, we are consistently calculating the leverage ratio based on the current credit agreement that clearly states that in addition to the standard adjustments related to IFRS 16 and others, they specifically disclose the non-recurring items on one hand, basically restructuring charges and transaction costs and all these things. In addition to that, they allow you to include as part of the EBITDA covenant, the amount of cost savings associated with operational improvement plans like this one on a run rate basis for the upcoming 12 months with a cap of 10% of the EBITDA. So that's the way that it is being calculated, but happy to provide you with a detailed reconciliation in case that you needed. Obviously, I mean, there is, you can do a quick math with the EBITDA that I provided to you with the adjustment that mainly has to be included. But as you said, clearly, it will depend on the size of the transaction, and it is going to be one or two. Finally, those will be the ones that will move the needle in 2023, but we'll reiterate the 4 times leverage target for 2024.

Hello. James Gordon from JPMorgan. Thanks for taking the question. I think some of the key ones have been asked. So I'll just do three quick clarifications. One was on the biopharma revenue guide, so the 10% to 12% growth, even though you could grow quicker than that in that you have enough plasma to do so. Is that because that's where demand is, that demand is actually the limiting factor, and there isn't even of easy comps or is it more demand than that? Or is it more about the fractional economics that you could grow more quickly than that, but you wouldn't be able to maintain the sort of EBITDA margins you want to now get to? And that was the first one. The second one, I think you said 28% to 29% EBITDA margin next year. Is that with or without Biotest, please? And could that be a bit conservative if you've also got operational leverage and underlying improvement and the EUR400 million of savings? And then the final clarification was just divestments. I think you said that everything is on the table. But is it now less likely that you look to divest some of older Shanghai RAAS given you want to retain exposure to China for strategic reasons or is that still as likely as doing a share collapse?

Thank you, James. This is Victor. I may take the first question. I may take the first question about the linking the 10% to 12% biopharma revenue growth for next year. This is a combination of many factors. We have, as you know, our hemophilia franchise, for instance, has been in the recent years impacted, and this continues to do so. Meaning by that, that IG, which is the lion's share of our sales and Alpha-1, both are growing nicely in a way above this 10% to 12%. So this kind of gives an indication that really there is solid demand there. We have the plasma that we need to fulfill those sales. And basically, this is the answer to your question, the third one.

To your question regarding the margin, the 28% to 29% for next year, which would be EUR1.7 billion, EUR1.8 billion with organic growth biotest contribution up to the time that we launch the new products will be the minimum. So it's all about stand-alone and combined; it's pretty much the same. The operational leverage, yes, obviously, this EUR400 million is basically, as you said, the result of a bunch of initiatives to achieve operational leverage, especially on the plasma cost and across the whole organization.

And let me just come back on the question of Shanghai RAAS and any of the other transactions that we are looking at or contemplating or that you might consider. We will obviously do nothing if it doesn't create value, and that also goes for the capital raise because we are obviously looking at this very carefully to make sure that we create the most value for the company. So I want to make sure that we are very much aligned on the fact that it is one of the options, but it is not necessarily the preferred option.

Yes. Good morning. Thank you for taking my question. So the first one on your plasma collection capacity versus pre-pandemic in 2023 following the restructuring that you plan to undertake. If you can compare it with your targets in terms of plasma collections that you mentioned that you don't need that much plasma for 2023 to fulfill met? And the second question is about the EUR400 million savings. Should we think about them on gross terms or net terms, including perhaps potential needs to reinvest in the business that you might have? Thank you.

Hi. I will take the first question. Again, now with Grifols, we are at a stage regarding plasma collection that we have the availability to collect the plasma volume that we need to meet our sales growth for the year. So on that side, we are basically now focusing on improving the productivity per center, meaning that we get the same plasma volume that we need, but if possible, at better efficiency and productivity levels to help us the margin expansion.

Regarding your question, the EUR400 million are net, and no additional investments would be required; it is all about streamlining our operational costs.

Hi. Good morning. So a couple of questions from my side. Regarding the target of EUR1.7 billion, which at first sight could look low. But obviously, you are not including Biotest EBITDA or any incremental EBITDA coming from sales growth in 2024. Would it be fair to say that when you add up these levers, also product mix and others, the EBITDA could be closer to EUR1.9 billion, EUR2 billion EBITDA or at least close to the consensus in 2024, which is right now EUR1,850 million? The second question would be regarding the donor fee. How much downside from current levels do you see? So is there room for further improvement or capping the donor fee more? And final question regarding free cash flow generation in 2023. How should we think about that figure? If you can provide any kind of magnitude range or at least qualitatively, how do you see the free cash flow improving this year? Thank you very much.

Two questions. So the first question, the EBITDA levels, on an annualized basis, as I said, this is EUR1.7 billion for 2023. For 2024, you need to add the organic growth, so clearly, it will exceed by far this EUR1.7 billion. Maybe we'll be close to your expectations. The donor fee, yes, we see that donor fees can be further optimized by discrimination of donor centers depending on the area, depending on whether there are competitors across the street or not. This is like any other business with pricing management, so there is room for improvement on the donor fee. On cash flow generation, this year is going to improve significantly versus 2022, first of all, because on the back of higher EBITDA, point number one. Point number two, lower working capital consumption because the inventory growth will be very limited. Lower CapEx, the EUR100 million lower CapEx than the previous year. So basically, due to those key three levers, the cash flow generation will be significant. But at this point in time, we will not provide specific details.

Yes. Thank you for taking my questions. So just one on the plasma collection for 2023. So I understand that you are managing the level of plasma you're going to collect going forward with the closure of some centers and the improvement in productivity in the remaining centers. I guess, if you think about the growth rate of collection in '23, probably in the first half of the year is going to be relatively high because your base is lower. But from the normalized base that you achieved in the fourth quarter of 2022, what is your ambition to grow collection further when we think about beyond 2023? So basically, should we see again an ambition to grow the volume and for example, expanding to new centers? Or are we going to remain in a mode where you're trying to manage your productivity by center rather than trying to expand new centers?

Thank you for the question. You nailed it at the end of your question. It's about we will manage volume, of course, by existing centers, but especially through productivity. We are not back to pre-pandemic levels productivity-wise. There is plenty of room for improvement to use the level of productivity per center to get the volume that we need and to align the volume needs with the sales needs.

Hi. Thank you very much for taking my questions. Two quick ones from me. Firstly, just on the deleveraging options. Can you just talk about the potential considerations you'll have to think about when thinking about exiting either part or all of the Shanghai RAAS stake? Are there any limitations there? Would you have to find a local player to sell the stake to? Just any more information around how that could actually be taken forward would be great. And then just secondly, on the potential impact of new competitors, say, you've got CIDP as a competitive threat this year. I'm just wondering to what extent you've reflected that in your kind of near and midterm guidance? Thanks.

Your first question, there are no limitation on the potential Shanghai RAAS divestment.

Regarding the competitive landscape in the immunomodulation market, FcRn blocker is specific to be more precise. Due to the mechanism of the disease itself, it's a very complex disease. Many factors are implied in the disease modality. We really don't expect that this may have a huge impact on our CIDP franchise. Therefore, we are not modeling as well that impacting our midterm projections. We expect this to be limited for CIDP.

Okay. It will be 50% coming from optimized donor fees and 50% from the rest basically, and as I said, I already gave you some details about the initiatives.

Hello. Thank you for taking my questions. I have three very quick ones. First one is regarding plasma collection centers. You've been adding new centers in the last few years, and you've said in the past that some of those centers had kind of legacy contracts with higher costs. I'm wondering what's the impact of the renewal of those contracts once they are renegotiated with better terms; are the impacts of those already embedded in your cost-saving guidance? Second, regarding the surprise collapse, sorry to be bothersome with this, do you have any kind of share price level at which you start considering the collapse? Is it 15 per share? Is it 20 per share? And finally, another bothersome question, just to clarify, could you please tell us if you are involved in any kind of talks, even if they are very preliminary, to dispose of any business of the Grifols Group? Thank you.

I'll take the first one. Thanks for the question. Yes, the operating performance improvement plan on plasma contemplates a blend of this kind of new centers that we have acquired in the pandemic plus some third-party contracts to get plasma from it. Yes, everything is contemplated. And as I said in previous questions, as an answer, everything that makes sense to consolidate or to close has either been done or will continue to be done during this year 2023 to really fine-tune this balance between volume and productivity.

Regarding the AMB unification, obviously, we need to look for the right spot, the right time and the right price. The right spot will be with the right gap and the right stock price; for the time being, we have not decided yet on these two factors. Of course, we will not disclose any talks regarding the potential deleverage transaction.

And I'll take the last one, and that is your specific question on where we are on any transaction. Obviously, that's very confidential, and I cannot go there. However, I want to again reiterate one point just to be very, very clear, and that is that we are not considering a capital raise at all, and that's not a favorite option at the current valuations that we have. So unless something dramatically changes in the valuations or our trading prices going forward, that is not really on the table. So it's not something that we are putting that really as a very last option.

Thank you, Thomas. We have a follow-up from Peter from Citi. Please, Peter, but be really fast.

Well, I think it will be very fast because I was looking for a clarification because I got worried about the comments last year at the CMD being no capital raise to all options being on the table. But I think Thomas has clarified that in terms of his previous comments, so I won't waste any more time. Thanks for the call.

Thank you anyway. And with that, we'll end our call today. You know that any other questions, the IR team is always available and any other conversations we can follow up in the next few days. Thank you very much for taking part. Bye.